Nov-15 -

Soft Tissue & Bone

EORTC 62024 – Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor : a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery.

Building on the successful results of its previous research on GIST, EORTC continued by determining the timing of treatment with imatinib in patients with early detected GIST. Through the EORTC GIST studies, life expectancy of patients diagnosed with this tumour has doubled. Thanks to EORTC, today, imatinib has changed the landscape of GIST treatment making it the gold standard.


Go to Top